

Curriculum vitae Maria Giulia Zampino, MD

Education

1986 Degree of Medicine, State University of Naples, Italy. Experimental Thesis on TCell Lymphomas (110/110 cum laude)

1989 Specialization in Oncology, State University of Naples, Italy. Experimental Thesis on TNF-alpha and cancer (70/70 cum laude)

Titles

Society Affiliations:

- Since 1988 AIOM (Associazione Italiana di Oncologia Medica)
- Since 1991 ESMO (European Society of Medical Oncology)
- Since 1993 ASCO (American Society of Clinical Oncology)

Clinical Activities carried out at IEO

- Coordinator of the clinical activity of the Medical Care Unit-Day Hospital and currently in charge with High Specialty Charge on lower gastrointestinal tract (small bowel, colorectal and anal cancer), at Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology IRCCS, Milan
- GI Board Member, responsible for the evaluation of complex clinical cases.
- Until 2012 active member of the IEO Committee "Clinical risk management and patient safety"

Research Activities carried out at IEO

- Principal Investigator in several spontaneous and sponsored studies Phase Ib/II/III clinical trials regarding colorectal and anal cancer, as well as looking for innovative models of integrated therapeutic strategies (neoadjuvant treatments, chemo-radiotherapy, locoregional approaches for liver and lung metastases).
- Clinical research oriented to evaluate predictive bio-markers of clinical response and / or prognostics in colorectal tumors in collaboration with research laboratories of IEO and IFOM.

Passed Clinical and Research Activities

- From 1990 to 1996: Fellowship at the Division of Medical Oncology II, National Cancer Institute of Milan followed by the role of Assistant at Oncology Institute of Basilicata (IRCCS, Rionero in Vulture-PZ) in collaboration with National Cancer Institute of Milan. Main clinical and scientific interest: breast cancer and cutaneous melanoma.

Publications

Author/coauthor of more than 100 publications in high impact international scientific journals. Among them:

[Cisplatin plus capecitabine concomitant with intensity-modulated radiation therapy in non-metastatic anal squamous cell carcinoma: the experience of a single research cancer center.](#) Rotundo MS, *Zampino MG*, Ravenda PS, Bagnardi V, Peveri G, Dell'Acqua V, Surgo A, Trovato C, Bottiglieri L, Bertani E, Petz WL, Fumagalli Romario U, Fazio N. Ther Adv Med Oncol. 2020

[FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial.](#) Sobrero A, Lonardi S, Rosati G, Di Bartolomeo M, Ronzoni M, Pella N, Scartozzi M, Banzi M, *Zampino MG*, Pasini F, Marchetti P, Cantore M, Zaniboni A, Rimassa L, Ciuffreda L, Ferrari D, Zagonel V, Maiello E, Barni S, Rulli E, Labianca R; TOSCA Investigators. J Clin Oncol. 2018

[Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis.](#) Vernieri C, Galli F, Ferrari L, Marchetti P, Lonardi S, Maiello E, Iaffaioli RV, *Zampino MG*, Zaniboni A, De Placido S, Banzi M, Damiani A, Ferrari D, Rosati G, Labianca RF, Bidoli P, Frassinetti GL, Nicolini M, Pavesi L, Tronconi MC, Buonadonna A, Ferrario S, Re GL, Adamo V, Tamburini E, Clerico M, Giordani P, Leonardi F, Barni S, Ciarlo A, Cavanna L, Gori S, Cinieri S, Faedi M, Aglietta M, Antista M, Dotti KF, Galli F, Di Bartolomeo M; TOSCA (Three or Six Colon Adjuvant) Investigators. Oncologist. 2019

[Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator \(ARC: Anal Cancer Response Classifier\).](#) Casadei-Gardini A, Montagnani F, Casadei C, Arcadipane F, Andrikou K, Aloï D, Prete AA, *Zampino MG*, Argentiero A, Pugliese G, Martini S, Iorio GC, Scartozzi M, Mistrangelo M, Fornaro L, Cassoni P, Marisi G, Dell'Acqua V, Ravenda PS, Lonardi S, Silvestris N, De Bari B, Ricardi U, Cascinu S, Franco P. Cancer Manag Res. 2019

[Phase III study with FOLFIRI + cetuximab versus FOLFIRI + cetuximab followed by cetuximab alone in RAS and BRAF WT mCRC.](#) Pinto C, Normanno N, Orlandi A, Fenizia F, Damato A, Maiello E, Tamburini E, Di Costanzo F, Tonini G, Bilancia D, Corsi D, Pisconti S, Ferrau F, Gori S, Daniele B, Zaniboni A, Soto Parra H, Frassinetti GL, Iaffaioli RV, Cassata A, *Zampino MG*, Repetto L, Calegari MA, Barone C; all the investigators of ERMES study group. Future Oncol. 2018

[Treatments for colorectal liver metastases: A new focus on a familiar concept.](#) *Zampino MG*, Magni E, Ravenda PS, Cella CA, Bonomo G, Della Vigna P, Galdy S, Spada F, Varano GM, Mauri G, Fazio N, Orsi F. Crit Rev Oncol Hematol. 2016

[The anti-EGFR monoclonal antibody cetuximab combined with chemotherapy triggers immunogenic cell death.](#) Pozzi C, Cuomo A, Spadoni I, Magni E, Silvola A, Conte A, Sigismund S, Ravenda PS, Bonaldi T, *Zampino MG*, Cancelliere C, Di Fiore PP, Bardelli A, Penna G and Rescigno M. Nat Med 2016.

[Preoperative versus postoperative docetaxel-cisplatin-fluorouracil \(TCF\) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial.](#) Fazio N, Biffi R, Maibach R, Hayoz S, Thierstein S, Brauchli P, Bernhard J, Stupp R, Andreoni B, Renne G, Crosta C, Morant R, Chiappa A, Luca F, *Zampino MG*, Huber O, Goldhirsch A, de Braud F, Roth AD. Ann Oncol. 2015

[Lung metastases from colorectal cancer: analysis of prognostic factors in a single institution study.](#)

Zampino MG, Maisonneuve P, Ravenda PS, Magni E, Casiraghi M, Solli P, Petrella F, Gasparri R, Galetta D, Borri A, Donghi S, Veronesi G, Spaggiari L. Ann Thorac Surg. 2014

[Combined therapies for the treatment of technically unresectable liver malignancies: bland embolization and radiofrequency thermal ablation within the same session.](#)

Bonomo G, Della Vigna P, Monfardini L, Orgera G, Chiappa A, Bianchi PP, *Zampino MG*, Orsi F. Cardiovasc Intervent Radiol. 2012

[Concurrent cisplatin, continuous infusion fluorouracil and radiotherapy followed by tailored consolidation treatment in non metastatic anal squamous cell carcinoma.](#)

Zampino MG, Magni E, Leonardi MC, Santoro L, Petazzi E, Fodor C, Petralia G, Trovato C, Nole' F, Orecchia R. BMC Cancer. 2011

[K-RAS status in squamous cell anal carcinoma \(SCC\): it's time for target-oriented treatment?](#)

Zampino MG, Magni E, Sonzogni A, Renne G. Cancer Chemother Pharmacol. 2009

[Rectal cancer.](#) *Zampino MG*, Labianca R, Beretta GD, et al. Crit Rev Oncol Hematol. 2009

[Capecitabine Initially Concomitant to Radiotherapy Then Perioperatively Administered in Locally Advanced Rectal Cancer.](#) *Zampino MG*, Magni E, Leonardi MC, et al. Int J Radiat Oncol Biol Phys. 2009

[Epidermal growth factor receptor serum \(sEGFR\) level may predict response in patients with EGFR positive advanced colorectal cancer treated with gefitinib?](#)

Zampino MG, Magni E, Santoro L, et al. Cancer Chemo and Pharmacol. 2008

[Independent prognostic value of fascin immunoreactivity in stage III-IV colonic adenocarcinoma.](#)

I Puppa G, Maisonneuve P, Sonzogni A, Masullo M, Chiappa A, Valerio M, *Zampino MG*, Franceschetti I, Capelli P, Chilosi M, Menestrina F, Viale G, Pelosi G. Br J Cancer. 2007

[First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer.](#)

Zampino MG, Magni E, Massacesi C et al, Cancer. 2007

Congresses

Squamous cell carcinoma antigen (SCCAg) and carcinoembryonic antigen (CEA) as prognostic biomarkers in anal squamous cell carcinoma. The experience of a single research center. M.R. Rotundo,...and *M.G.Zampino*. AIOM 2019 (Poster Session)

Circulating t-DNA as predictive factor in patients treated with neoadjuvant chemo-radiotherapy for locally advanced rectal cancer. M.S Rotundo,...and *MG Zampino* AIOM 2018 (Poster session)

Predictive value of circulating tumor-derived (ctDNA) in patients with locally advanced rectal cancer (LARC) treated with neoadjuvant chemo-radiotherapy (CT/RT). Preliminary results. P.S. Ravenda,...and *M.G. Zampino* ESMO WGI 2018

First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the Italian Research Group for Digestive Tract Cancer (GISCAD) CENTRAL (ColorEctalvastiNTRiALLdh) and SENTRAL (Serum angiogenesisCENTRAL) analysis. Scartozzi M, ... *Zampino MG*...and S. Cascinu ASCO Meeting 2016

Three or six months of adjuvant chemotherapy for colon cancer: Compliance and safety of the phase III Italian TOSCA trial. Lonardi S, Labianca R, DiBartolomeo M, Gianni L, Pella N, Massidda B, Boni C, *Zampino MG*,...Sobrero A. ESMO Meeting 2014 (Oral presentation)